Isolation and structure elucidation of the main UV-A photoproducts of vandetanib

Journal of Pharmaceutical and Biomedical Analysis

Volumn 84, Issue , 2013, Pages 196-200

  Dall'Acqua, Stefano ^a   Vedaldi, Daniela ^a   Salvador, Alessia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

HPLC; Photoproduct; Photostability; Phototoxicity; Vandetanib

Indexed keywords

(2 FLUOROPHENYL) 6 METHOXY 7 [(1 METHYLPIPERIDIN 4 YL) METHOXY]QUINAZOLIN 4 AMINE; BROMIDE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB;

AQUEOUS SOLUTION; ARTICLE; DEBROMINATION; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTODEGRADATION; PHOTOLYSIS; PRIORITY JOURNAL; RADIATION DETECTOR; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRAVIOLET A RADIATION;

HPLC; PHOTOPRODUCT; PHOTOSTABILITY; PHOTOTOXICITY; VANDETANIB;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHOTOCHEMISTRY; PHOTOLYSIS; PIPERIDINES; QUINAZOLINES; SOLUTIONS; SOLVENTS; ULTRAVIOLET RAYS;

EID: 84880351061     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.05.049     Document Type: Article

References (18)

1. Mullard A. FDA drug approvals. Nat. Rev. Drug Discov. 2012, 11:91-94.
2. Ryan A.J., Wedge S.R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer 2005, 92:S6-S13.
3. Langmuir P.B., Yver A. Vandetanib for the treatment of thyroid cancer. Clin. Pharmacol. Therap. 2012, 91:71-80.
4. Leboulleux S., Bastholt L., Krause T., de la Fauchardiere C., Tennvall J., Awada A., Gómez J.M., Bonichon F., Leenhardt L., Soufflet C., Licour M., Schlumberger M.J. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012, 13:897-905.
5. Xiao Y.Y., Zhan P., Yuan D.M., Lv H.B., Shi Y., Song Y. Chemotherapy plus vandetanib or chemotherapy alone in advance non-small cell lung cancer: a meta analysis of four randomised controlled trials. Clin. Oncol. 2013, 25:e7-e15.
6. Drappatz J., Norden A.D., Worng E.T., Doherty L.M., LaFrankie D.C., Ciampa A., Kesari S., Sceppa C., Gerard M., Phan P., Schiff D., Batchelor T.T., Ligon K.L., Young G., Muzikansky A., Weiss S.E., Wen P.Y. Phase I Study of vandetanib with radiotherapy and temozolomide for newly diagnised gliobastoma. Int. J. Rad. Oncol. Biol. Phys. 2010, 78:85-90.
7. Degrauwe N., Sosa J.A., Roman S., Desphande H.A. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin. Med. Insights Oncol. 2012, 6:243-252.
8. Myskowski P.L., Halpern A.C. Skin reactions to the new biologic anticancer drugs. Curr. Opin. Palliat. Care 2009, 3:294-299.
9. Kong H.H., Fine H.A., Stern J.B., Chanco Turner M.L. Cutaneous pigmantation after photosensitivity induced by vandetanib therapy. Arch. Dermatol. 2009, 145:923-925.
10. Fava P., Quaglino P., Fierro M.T., Novelli M., Berengo M.G. A rare vandetanib-induced photo-allergic drug eruption. Dermatol. Ther. 2010, 23:553-555.
11. Chang C.H., Chang J.W., Hui C.Y., Yang C.H. Severe photosensitivity reaction to vandetanib. J. Clin. Oncol. 2009, 27:e114-e115.
12. Beijersbergen van Henegouwen G.M.J. Medicinal photochemistry: phototoxic and phototherapeutic aspects of drugs. Adv. Drug Res. 1997, 29:79-170.
13. Viola G., Grobelny P., Linardi M.A., Salvador A., Basso G., Mielcarek J., Dall'Acqua S., Vedaldi D., Dall'Acqua F. The phototoxicity of fluvastatin, an HMG.CoA reductase inhibitor, is mediated by the formation of benzocarbazole-like photoproduct. Toxicol. Sci, 2010, 118:236-250.
14. Viola G., Grobelny P., Linardi M.A., Salvador A., Dall'Acqua S., Sobotta L., Mielcarek J., Dall'Acqua F., Vedaldi D., Basso G. Arch. Toxicol 2012, 86:483-496.
15. Miolo G., Marzano C., Gandin V., Palozzo A.C., Dalzoppo D., Salvador A., Caffieri S. Photoreactivity of 5-fluorouracil under UVB light: photolysis and cytototoxicity studies. Chem. Res. Toxicol. 2011, 24:1319-1326.
16. CH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Photostability Testing of New Drug Substances and Products, Q1B, 1996.
17. Aman W., Thoma K. The influence of formulation and manufacturing process on the photostability of tablets. Int. J. Pharm. 2008, 28:33-41.
18. Bai F., Johnson J., Wang F., Yang L., Broniscer A., Stewart C.F. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:2561-2566.